Response to: ‘Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms’ by Reginster et al

We appreciate the interest that Reginster and colleagues1 showed in our publication on subgroup effects of oral glucosamine for osteoarthritis (OA).2 We are pleased that the eLetter authors do not put forward any critique of our publication that requires our justification or clarification. As highlighted by the authors,1 the effectiveness of oral glucosamine products for knee and hip OA symptoms has been questioned. Nevertheless, due to the heterogeneous nature of the disease, whether certain subgroups of patients with OA could benefit from glucosamine has not been excluded. Since available randomised controlled trials are usually not …